Back to top
more

Prana Biotechnology (ATHE)

(Delayed Data from NSDQ)

$1.29 USD

1.29
3,373

-0.02 (-1.15%)

Updated Sep 17, 2024 03:05 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 31% (79 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Balance Sheet

Research for ATHE

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

Fiscal Year End for Prana Biotechnology Ltd falls in the month of June.

All items in Millions except Per Share data.

6/30/2024 6/30/2023 6/30/2022 6/30/2021 6/30/2020
Assets          
Cash & Equivalents 8 11 25 21 6
Receivables 3 6 3 3 0
Notes Receivable NA 0 0 0 0
Inventories NA 0 0 0 0
Other Current Assets 2 2 1 1 0
Total Current Assets 12 18 30 25 7
Net Property & Equipment 0 0 0 0 0
Investments & Advances NA 0 0 0 0
Other Non-Current Assets NA 0 0 0 0
Deferred Charges NA 0 0 0 0
Intangibles NA 0 0 0 0
Deposits & Other Assets NA 0 0 0 0
Total Assets 13 18 30 25 7
Liabilities & Shareholders Equity 6/30/2024 6/30/2023 6/30/2022 6/30/2021 6/30/2020
Notes Payable NA 0 0 0 0
Accounts Payable 3 2 4 2 1
Current Portion Long-Term Debt NA 0 0 0 0
Current Portion Capital Leases NA 0 0 0 0
Accrued Expenses NA 0 0 0 0
Income Taxes Payable 0 0 0 0 0
Other Current Liabilities 0 0 0 0 0
Total Current Liabilities 4 3 4 2 2
Mortgages NA 0 0 0 0
Deferred Taxes/Income NA 0 0 0 0
Convertible Debt NA 0 0 0 0
Long-Term Debt NA 0 0 0 0
Non-Current Capital Leases NA 0 0 0 0
Other Non-Current Liabilities NA 0 0 0 0
Minority Interest (Liabilities) NA 0 0 0 0
Total Liabilities 4 3 4 2 2
Shareholders Equity 6/30/2024 6/30/2023 6/30/2022 6/30/2021 6/30/2020
Preferred Stock NA 0 0 0 0
Common Stock (Par) 146 144 155 148 108
Capital Surplus NA 0 0 0 0
Retained Earnings -140 -131 -132 -127 -104
Other Equity 3 3 3 2 1
Treasury Stock NA 0 0 0 0
Total Shareholder's Equity 9 15 26 23 5
Total Liabilities & Shareholder's Equity 13 18 30 25 7
Total Common Equity 100,008 15 26 23 5
Shares Outstanding 7.30 4.00 4.00 2.20 1.40
Book Value Per Share 13,699.73 3.84 6.43 10.35 3.43

Fiscal Year End for Prana Biotechnology Ltd falls in the month of June.

All items in Millions except Per Share data.

6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023
Assets          
Cash & Equivalents -99,991 -99,999 -99,991 -99,999 11
Receivables 3 NA 4 NA 6
Notes Receivable NA NA NA NA 0
Inventories NA NA NA NA 0
Other Current Assets 2 NA 2 NA 2
Total Current Assets 12 NA 14 NA 18
Net Property & Equipment 0 NA 0 NA 0
Investments & Advances NA NA NA NA 0
Other Non-Current Assets NA NA NA NA 0
Deferred Charges NA NA NA NA 0
Intangibles NA NA NA NA 0
Deposits & Other Assets NA NA NA NA 0
Total Assets 13 NA 14 NA 18
Liabilities & Shareholders Equity 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023
Notes Payable NA NA NA NA 0
Accounts Payable 3 NA 2 NA 2
Current Portion Long-Term Debt NA NA NA NA 0
Current Portion Capital Leases NA NA NA NA 0
Accrued Expenses NA NA NA NA 0
Income Taxes Payable 0 NA 0 NA 0
Other Current Liabilities 0 NA 1 NA 0
Total Current Liabilities 4 NA 3 NA 3
Mortgages NA NA NA NA 0
Deferred Taxes/Income NA NA NA NA 0
Convertible Debt NA NA NA NA 0
Long-Term Debt NA NA NA NA 0
Non-Current Capital Leases NA NA NA NA 0
Other Non-Current Liabilities NA 0 NA 0
Minority Interest (Liabilities) NA NA NA NA 0
Total Liabilities 4 NA 3 NA 3
Shareholders Equity 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023
Preferred Stock NA NA NA NA 0
Common Stock (Par) 146 NA 140 NA 144
Capital Surplus NA NA NA NA 0
Retained Earnings -140 NA -131 NA -131
Other Equity 3 NA 3 NA 3
Treasury Stock NA NA NA NA 0
Total Shareholder's Equity 9 NA 11 NA 15
Total Liabilities & Shareholder's Equity 13 NA 14 NA 18
Total Common Equity 100,008 0 100,010 0 15
Shares Outstanding 7.30 7.30 4.60 4.00 4.00
Book Value Per Share 13,699.73 0.00 21,741.41 0.00 3.84